天臣医疗(688013) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2021 reached CNY 45.83 million, a 50.05% increase year-on-year[6] - Net profit attributable to shareholders was CNY 12.94 million, up 115.39% from the same period last year[6] - Basic and diluted earnings per share were both CNY 0.16, representing a 60.00% increase year-on-year[6] - Total revenue for Q1 2021 was ¥45,832,956.17, representing a 50.05% increase compared to ¥30,544,697.75 in Q1 2020, driven by sales growth[16] - Net profit for Q1 2021 was ¥12,939,825.97, representing a 115.0% increase compared to ¥6,007,755.22 in Q1 2020[30] - Operating profit for Q1 2021 was ¥14,605,126.27, an increase of 158.5% from ¥5,654,185.42 in Q1 2020[30] - The total comprehensive income for Q1 2021 was ¥13,032,248.48, an increase of 116.9% from ¥6,008,190.92 in Q1 2020[31] Assets and Liabilities - Total assets increased by 3.99% to CNY 504.62 million compared to the end of the previous year[6] - The company’s total assets as of March 31, 2021, included trading financial assets of ¥337,632,905.48, an increase of 33.69% from the previous period[16] - Total assets increased to CNY 504,619,932.96 as of March 31, 2021, up from CNY 485,243,095.67 at the end of 2020, representing a growth of approximately 2.8%[20] - Total liabilities rose to CNY 25,695,037.63 from CNY 19,350,448.82, marking an increase of about 32.9%[22] - The company reported a significant increase in accounts payable, which rose to CNY 10,127,687.22 from CNY 3,065,594.77, an increase of approximately 230.5%[21] Cash Flow - Cash flow from operating activities was CNY 14.81 million, a significant increase of 773.31% compared to the previous year[6] - The net cash flow from operating activities increased significantly by 773.31% to ¥14,809,824.12, attributed to higher sales revenue[17] - In Q1 2021, the company generated cash inflow from operating activities amounting to ¥52,909,258.30, a 51.8% increase from ¥34,868,177.35 in Q1 2020[34] - The company reported cash inflow from investment activities of ¥172,891,736.75 in Q1 2021, compared to only ¥2,215,353.22 in Q1 2020, indicating a substantial increase[35] - The company experienced a net decrease in cash and cash equivalents of ¥68,145,484.17 in Q1 2021, compared to a decrease of ¥2,877,598.86 in Q1 2020[35] Research and Development - R&D expenses amounted to CNY 3.78 million, a 15.37% increase year-on-year, with R&D investment accounting for 8.24% of operating revenue[8] - Research and development expenses for Q1 2021 totaled ¥3,775,416.79, up 15.4% from ¥3,272,532.68 in Q1 2020[29] Shareholder Information - The company had a total of 4,537 shareholders at the end of the reporting period[12] - The top two shareholders, Chen Wangyu and Chen Wangdong, held 26.22% and 26.17% of shares, respectively[12]